The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Monthly Ranibizumab Injections

Trial Profile

The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Monthly Ranibizumab Injections

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms SHIFT2
  • Most Recent Events

    • 12 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017, as reported by ClinicalTrials.gov record.
    • 12 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2017, as reported by ClinicalTrials.gov record.
    • 14 Apr 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top